BioLineRX
BLRX
12 hedge funds and large institutions have $28K invested in BioLineRX in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 23 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% less ownership
Funds ownership: 0% → 0% (-0%)
61% less funds holding
Funds holding: 31 → 12 (-19)
83% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 23
94% less capital invested
Capital invested by funds: $436K → $28K (-$408K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$11.5K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.84K |
| 3 |
JP Morgan Chase
New York
|
+$1.51K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.26K |
| 5 |
Morgan Stanley
New York
|
+$1.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$215K |
| 2 |
VFA
Values First Advisors
Gray,
Tennessee
|
-$35.6K |
| 3 |
AWS
Atria Wealth Solutions
New York
|
-$20.1K |
| 4 |
LPL Financial
San Diego,
California
|
-$19.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18.5K |
BLRX Hedge Fund Activity: Q1 2025 in Review
12 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2025, worth a combined $28K — down 94% from $436K a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of BLRX and 4 opened new positions — a net loss of 19 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Wells Fargo, adding an estimated $11.5K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $215K sold.
- 12 institutional investors held BioLineRX (BLRX) as of Q1 2025, down from 31 in Q4 2024.
- Funds reported $28K of BioLineRX stock for Q1 2025, down 94% quarter-over-quarter.
- 4 funds opened new BioLineRX positions in Q1 2025 and 23 closed out, a net change of -19 holders.
- The largest BioLineRX buyer in Q1 2025 was Wells Fargo, an estimated $11.5K added.
- The largest BioLineRX seller in Q1 2025 was Highbridge Capital Management, an estimated $215K sold.
Based on aggregated 13F filings for Q1 2025.